Amendments to the Claims

Please cancel original claims 1 through 20 and add the following new claims:

1-20. (Cancelled)

21. (New) A method of treating a patient suffering from thrombotic thrombocytopenic purpura (TTP) which comprises, administering to said patient a dosage of about 1 μg/kg/hr to about 50 μg/kg/hr of recombinant human protein C.

22. (New) The method of Claim 21 wherein the dosage is about 6 μg/kg/hr to about 36 μg/kg/hr of recombinant human protein C.

23. (New) The method of Claim 22 wherein the recombinant human protein C is recombinant human protein C zymogen.

24. (New) The method of Claim 22 wherein the recombinant human protein C is recombinant human activated protein C.

25. (New) The method of Claim 24, wherein the recombinant human activated protein C is administered by continuous infusion for about 48 to about 240 hours.

26. (New) A method of treating thrombotic thrombocytopenic purpura (TTP) in a patient in need thereof, which comprises administering to said patient a pharmaceutically effective amount of recombinant human activated protein C such that a recombinant human activated protein C plasma level of about 2 ng/ml to about 200 ng/ml is achieved.

27. (New) The method of Claim 26 wherein the recombinant human activated protein C is administered by continuous infusion for about 48 to about 240 hours.

28. (New) The method of Claim 26 wherein the recombinant human activated protein C is administered first as a bolus then as a continuous infusion.

29. (New) A method of treating a patient suffering from hemolytic uremic syndrome (HUS) which comprises, administering to said patient a dosage of about 1 μg/kg/hr to about 50 μg/kg/hr of recombinant human protein C.

30. (New) The method of Claim 29 wherein the dosage is about 6 μg/kg/hr to about 36 μg/kg/hr of recombinant human protein C.

31. (New) The method of Claim 30 wherein the recombinant human protein C is recombinant human protein C zymogen.

32. (New) The method of Claim 30 wherein the recombinant human protein C is recombinant human activated protein C.

33. (New) The method of Claim 32, wherein the recombinant human activated protein C is administered by continuous infusion for about 48 to about 240 hours.

34. (New) A method of treating hemolytic uremic syndrome (HUS) in a patient in need thereof, which comprises administering to said patient a pharmaceutically effective amount of recombinant human activated protein C such that a recombinant human activated protein C plasma level of about 2 ng/ml to about 200 ng/ml is achieved.

35. (New) The method of Claim 34 wherein the recombinant human activated protein C is administered by continuous infusion for about 48 to about 240 hours.

36. (New) The method of Claim 34 wherein the recombinant human activated protein C is administered first as a bolus then as a continuous infusion.